LoadingLoadingLoadingNet selling: insiders sold $8.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
Citadel
$34.8M
added
Susquehanna
$18.1M
added
Sells/Trims (1)
Balyasny
$29.7M
trimmed
No tracked top-trader positions in PTCT as of Oct 21, 18:00 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.34 expected
Revenue
Financial statements: Alpha Vantage
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $0.92 / $0.34Yahoo Finance | +$0.58 beat | $360.5M No estimate | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$0.03 / -$0.44Yahoo Finance | +93.18% beat | $272.6M No estimate | Unavailable |
| Dec 31, 2025 | Feb 19, 2026 | -$1.80 / -$0.41Yahoo Finance | -$1.39 miss | $164.7M No estimate | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $0.19 / -$1.11Yahoo Finance | +116.88% beat | $211.0M No estimate | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$0.83 / -$1.07Alpha Vantage | +22.43% beat | $178.9M No estimate | Unavailable |
| Mar 31, 2025 | May 6, 2025 | $10.04 / -$0.70Alpha Vantage | +$10.74 beat | $1.18B No estimate | Unavailable |
| Dec 31, 2024 | Feb 27, 2025 | -$0.34 / -$0.65Alpha Vantage | +47.45% beat | $213.2M No estimate | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | -$1.36 / -$1.66Alpha Vantage | +18.07% beat | $196.8M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $211.0M | $164.7M | $272.6M | $360.5M |
| Cost of what it sold | $115.9M | $16.3M | $28.0M | $19.9M |
| Gross profit | $95.1M | $148.4M | $244.5M | $340.6M |
| What it spent | ||||
| Research and development | $100.2M | $133.1M | $100.9M | $99.2M |
| Sales and admin | $84.0M | $96.9M | $86.2M | $80.6M |
| Other operating costs | -$92.2M | — | $11.6M | $11.8M |
| Total operating expenses | $92.1M | $230.0M | $198.6M | $191.6M |
| What was left | ||||
| Operating profit | $3.0M | -$81.6M | $45.9M | $149.0M |
| Interest on debt | $32.6M | $55.2M | $49.0M | $48.5M |
| Profit before tax | -$23.1M | -$139.1M | -$2.5M | $97.5M |
| Tax | -$39.0M | -$4.1M | $347.0K | $14.0M |
| Net profit | $15.9M | -$135.0M | -$2.8M | $83.5M |
| EBITDA | $20.6M | -$71.0M | $62.0M | $161.9M |
This stock is under pressure.
Trend
Under pressure
20 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Raised to "Strong-Buy" at UBS Group
NeutralOct 17Truist sets USD 62.00 target for PTC Therapeutics stock
BullishOct 17PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company Stock
Leans bearishOct 17Form 4 PTC Therapeutics Inc: Michael Schmertzler (Director) For: 14 October
NeutralOct 17Form 4 PTC Therapeutics Inc: Michael Schmertzler (Director) For: 14 October
NeutralOct 17PTCT Upgraded by UBS -- Price Target Raised to $90.00
Leans bullishOct 16Planned sales of 2,118 and 382 PTC Therapeutics (PTCT) shares came from Section Six Partners.
Leans bearishOct 16PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist Financial
Leans bullishOct 16
